Molecular pathogenesis and mechanisms of thyroid cancer
M Xing - Nature Reviews Cancer, 2013 - nature.com
Thyroid cancer is a common endocrine malignancy. There has been exciting progress in
understanding its molecular pathogenesis in recent years, as best exemplified by the …
understanding its molecular pathogenesis in recent years, as best exemplified by the …
[HTML][HTML] TERT promoter mutations in thyroid cancer
R Liu, M Xing - Endocrine-related cancer, 2016 - erc.bioscientifica.com
The 2013 discovery of Telomerase reverse transcriptase (TERT) promoter mutations chr5,
1,295,228 C> T (C228T) and 1,295,250 C> T (C250T) in thyroid cancer represents an …
1,295,228 C> T (C228T) and 1,295,250 C> T (C250T) in thyroid cancer represents an …
Functions of thrombospondin-1 in the tumor microenvironment
The identification of thrombospondin-1 as an angiogenesis inhibitor in 1990 prompted
interest in its role in cancer biology and potential as a therapeutic target. Decreased …
interest in its role in cancer biology and potential as a therapeutic target. Decreased …
Exosome mimetics: a novel class of drug delivery systems
SAA Kooijmans, P Vader… - International journal …, 2012 - Taylor & Francis
The identification of extracellular phospholipid vesicles as conveyors of cellular information
has created excitement in the field of drug delivery. Biological therapeutics, including short …
has created excitement in the field of drug delivery. Biological therapeutics, including short …
The thrombospondins
JC Adams, J Lawler - Cold Spring Harbor perspectives …, 2011 - cshperspectives.cshlp.org
Thrombospondins are evolutionarily conserved, calcium-binding glycoproteins that undergo
transient or longer-term interactions with other extracellular matrix components. They share …
transient or longer-term interactions with other extracellular matrix components. They share …
The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: A meta‐analysis
BACKGROUND: The effects of the BRAFV600E mutation on prognostic factors and poor
clinical outcomes in papillary thyroid cancer (PTC) have not been fully quantified. The …
clinical outcomes in papillary thyroid cancer (PTC) have not been fully quantified. The …
TERT Promoter Mutations and Their Association with BRAF V600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer
Context: Promoter mutations chr5: 1,295,228 C> T and chr5: 1,295,250 C> T (termed C228T
and C250T, respectively) in the gene for telomerase reverse transcriptase (TERT) have …
and C250T, respectively) in the gene for telomerase reverse transcriptase (TERT) have …
[HTML][HTML] Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation
D Chakravarty, E Santos, M Ryder… - The Journal of …, 2011 - Am Soc Clin Investig
Advanced human thyroid cancers, particularly those that are refractory to treatment with
radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene …
radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene …
Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants
X Shi, R Liu, F Basolo, R Giannini… - The Journal of …, 2016 - academic.oup.com
Context: Individualized management, incorporating papillary thyroid cancer (PTC) variant-
specific risk, is conceivably a useful treatment strategy for PTC, which awaits comprehensive …
specific risk, is conceivably a useful treatment strategy for PTC, which awaits comprehensive …
[HTML][HTML] Thrombospondin-1 is a multifaceted player in tumor progression
T Huang, L Sun, X Yuan, H Qiu - Oncotarget, 2017 - ncbi.nlm.nih.gov
Thrombospondins are a family of extracellular matrix (ECM) proteins. Thrombospondin-1
(TSP1) was the first member to be identified and is a main player in tumor microenvironment …
(TSP1) was the first member to be identified and is a main player in tumor microenvironment …